{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.69","upperLimit":"10.28","value":"5.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Hepatocellular Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.87","upperLimit":"2.92","value":"1.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Triple Negative Breast Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"6.24","upperLimit":"NA","value":"16.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Immune Checkpoint-naïve Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.25","upperLimit":"2.14","value":"1.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Primary Refractory Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.14","upperLimit":"4.21","value":"2.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Relapsed Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.14","upperLimit":"7.36","value":"4.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"NSCLC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.33","upperLimit":"6.24","value":"4.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Renal Cell Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.30","upperLimit":"7.79","value":"4.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Squamous Cell Carcinoma of the Head and Neck"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.14","upperLimit":"8.90","value":"4.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Transitional Cell Carcinoma of the GU Tract"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.97","upperLimit":"2.83","value":"2.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.07","value":"1.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Gastric Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"2.07","upperLimit":"NA","value":"6.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"MSI high Colorectal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.87","upperLimit":"4.01","value":"2.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"DLBCL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"382"}],"units":"Participants"}],"description":"Progression-free survival is defined as number of days from the first day of taking study drug to the earlier of death or disease progression by irRECIST v1.1 for select solid tumors and modified Lugano Classification for DLBCL.","dispersionType":"90% Confidence Interval","groups":[{"description":"Epacadostat 100 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 200 mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG000","title":"Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W"}],"paramType":"MEDIAN","populationDescription":"The efficacy evaluable population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab).\n\nNumber analyzed indicated participants analyzed in the respective tumor type.","reportingStatus":"POSTED","timeFrame":"Up to 54 months","title":"Phase 2: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}